Stock Analysis on Net

Eli Lilly & Co. (NYSE:LLY)

$24.99

Enterprise Value to FCFF (EV/FCFF)

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Free Cash Flow to The Firm (FCFF)

Eli Lilly & Co., FCFF calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net income
Net noncash charges
Other changes in operating assets and liabilities, net of acquisitions and divestitures
Net cash provided by operating activities
Cash payments for interest on borrowings, net of tax1
Purchases of property and equipment
Free cash flow to the firm (FCFF)

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The financial information reveals fluctuations in both net cash provided by operating activities and free cash flow to the firm (FCFF) over the five-year period. A significant decrease in FCFF is observed between 2021 and 2023, followed by substantial increases in both metrics in subsequent years.

Net Cash from Operations
Net cash provided by operating activities decreased from US$7,261 million in 2021 to US$7,084 million in 2022, representing a modest decline. A more pronounced decrease occurred in 2023, falling to US$4,240 million. However, a strong recovery is evident in 2024, with operating cash flow rising to US$8,818 million, and continuing to increase significantly in 2025, reaching US$16,813 million. This indicates improving operational efficiency and/or increased profitability in the later years of the period.
Free Cash Flow to the Firm (FCFF)
FCFF followed a similar pattern to operating cash flow. It decreased from US$6,257 million in 2021 to US$5,527 million in 2022. The most substantial decline occurred between 2022 and 2023, with FCFF plummeting to US$1,116 million. A considerable rebound is then observed, with FCFF increasing to US$4,242 million in 2024 and further to US$9,480 million in 2025. This suggests that the company’s ability to generate cash available to all investors (debt and equity holders) improved markedly in the latter part of the period.

The divergence between the decline in operating cash flow in 2023 and the even more significant decline in FCFF during the same period suggests a potential increase in investments in capital expenditures or other uses of cash that reduce cash available to the firm. The subsequent recoveries in both metrics from 2024 onwards indicate a reversal of these trends, potentially due to reduced capital spending or improved operational performance. The substantial growth in both metrics in 2025 is particularly noteworthy and warrants further investigation to understand the underlying drivers.


Interest Paid, Net of Tax

Eli Lilly & Co., interest paid, net of tax calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Effective Income Tax Rate (EITR)
EITR1
Interest Paid, Net of Tax
Cash payments for interest on borrowings, before tax
Less: Cash payments for interest on borrowings, tax2
Cash payments for interest on borrowings, net of tax

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 See details »

2 2025 Calculation
Cash payments for interest on borrowings, tax = Cash payments for interest on borrowings × EITR
= × =


The analysis reveals a fluctuating relationship between cash payments for interest on borrowings, net of tax, and the effective income tax rate over the five-year period. Cash payments for interest demonstrate an overall increasing trend, while the effective income tax rate exhibits considerable volatility.

Cash Payments for Interest
Cash payments for interest on borrowings, net of tax, remained relatively stable between 2021 and 2023, registering 306, 297, and 323 US$ millions respectively. A significant increase is observed in 2024, rising to 482 US$ millions, and continues to increase in 2025, reaching 508 US$ millions. This suggests a growing interest expense burden over the latter part of the analyzed period.
Effective Income Tax Rate
The effective income tax rate experienced a decrease from 9.32% in 2021 to 8.25% in 2022. A substantial increase occurred in 2023, reaching 20.05%, followed by a decline to 16.49% in 2024. The rate then increased again in 2025 to 19.80%. This volatility indicates potential changes in the company’s income mix, tax planning strategies, or applicable tax laws.
Relationship between Interest Payments and Tax Rate
While the effective income tax rate decreased in 2022, cash payments for interest also decreased slightly. However, the subsequent increase in the effective income tax rate in 2023 did not prevent a further increase in interest payments in 2024 and 2025. This decoupling suggests that factors beyond the tax rate, such as increased borrowing or higher interest rates, are driving the rise in interest expense. The net-of-tax presentation of interest payments means the impact of the tax rate on the actual cash outflow is already factored in, but the overall trend of increasing payments remains noteworthy.

In summary, the company experienced a growing interest expense despite fluctuations in the effective income tax rate. Further investigation into the drivers of both the increasing interest payments and the volatile tax rate would be beneficial.


Enterprise Value to FCFF Ratio, Current

Eli Lilly & Co., current EV/FCFF calculation, comparison to benchmarks

Microsoft Excel
Selected Financial Data (US$ in millions)
Enterprise value (EV)
Free cash flow to the firm (FCFF)
Valuation Ratio
EV/FCFF
Benchmarks
EV/FCFF, Competitors1
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
EV/FCFF, Sector
Pharmaceuticals, Biotechnology & Life Sciences
EV/FCFF, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31).

1 Click competitor name to see calculations.

If the company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.
Otherwise, if the company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.


Enterprise Value to FCFF Ratio, Historical

Eli Lilly & Co., historical EV/FCFF calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Enterprise value (EV)1
Free cash flow to the firm (FCFF)2
Valuation Ratio
EV/FCFF3
Benchmarks
EV/FCFF, Competitors4
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
EV/FCFF, Sector
Pharmaceuticals, Biotechnology & Life Sciences
EV/FCFF, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 See details »

2 See details »

3 2025 Calculation
EV/FCFF = EV ÷ FCFF
= ÷ =

4 Click competitor name to see calculations.


The Enterprise Value to Free Cash Flow to the Firm (EV/FCFF) ratio exhibits significant fluctuations over the observed period. Initially, the ratio demonstrates an increasing trend, followed by substantial volatility and a subsequent decline towards the end of the period.

Enterprise Value (EV)
Enterprise Value consistently increased throughout the period, rising from US$240,196 million in 2021 to US$1,014,695 million in 2025. The most substantial increase occurred between 2022 and 2023, with a growth of approximately 132.2%.
Free Cash Flow to the Firm (FCFF)
Free Cash Flow to the Firm experienced a decrease from US$6,257 million in 2021 to US$5,527 million in 2022. A significant drop was observed in 2023, falling to US$1,116 million. FCFF then recovered in 2024 to US$4,242 million and continued to increase substantially in 2025, reaching US$9,480 million.
EV/FCFF Ratio
The EV/FCFF ratio increased from 38.39 in 2021 to 59.17 in 2022, indicating a less favorable valuation based on free cash flow. A dramatic increase occurred in 2023, reaching 655.43, driven by the substantial decline in FCFF. The ratio decreased significantly in 2024 to 200.96, reflecting the recovery in FCFF. This downward trend continued into 2025, with the ratio further decreasing to 107.04, suggesting an improved valuation relative to free cash flow generation.

The large fluctuations in the EV/FCFF ratio suggest a dynamic relationship between the company’s enterprise value and its free cash flow generation. The significant increase in 2023 warrants further investigation to understand the underlying factors contributing to the decline in FCFF during that year. The subsequent recovery in FCFF and the corresponding decrease in the EV/FCFF ratio in 2024 and 2025 indicate a potential stabilization of the valuation.